A randomized, open-label study of PEGASYS plus 2 different doses of ribavirin on sustained virological response in patients with chronic hepatitis C viral infection, genotype 2 or 3.

Trial Profile

A randomized, open-label study of PEGASYS plus 2 different doses of ribavirin on sustained virological response in patients with chronic hepatitis C viral infection, genotype 2 or 3.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Ribavirin (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 09 Dec 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 26 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top